Gomez LCT oligometastatic NSCLC (long-term results)
ForStage IV NSCLC, ≤3 mets, no progression after front-line systemic therapy
14.2 vs 4.4 mo
median PFS, 95% CI 7.4-23.1 vs 2.2-8.3, P = .022
TL;DRmOS 41.2 vs 17.0 mo (P=.017) and mPFS 14.2 vs 4.4 mo favoring LCT over maintenance/observation in oligometastatic NSCLC after front-line therapy.
The OS gap tracks survival after progression, 37.6 vs 9.4 mo: only 15 of 39 progressors (41%) got LCT at progression, and in the MT/O arm 7 were blocked by polymetastatic progression. That argues for consolidating every site while disease is still oligometastatic, not holding RT for progression. Dose and fractionation are not in source text.
In stage IV NSCLC with ≤3 metastases and no progression after front-line platinum doublet, EGFR TKI or crizotinib, this supports consolidating all sites over maintenance alone; it does not extend to IO-treated pts, >3 metastases, or disease progressing on first-line therapy.
The OS gap tracks survival after progression, 37.6 vs 9.4 mo, and 7 MT/O progressors lost LCT eligibility to polymetastatic progression. That argues for consolidating every site while still oligometastatic rather than reserving RT for progression; dose and fractionation are not in source text.
Maintenance or observation was the comparator, and adding LCT gave mOS 41.2 vs 17.0 mo on a pre-IO backbone of platinum doublet, EGFR TKI or crizotinib. Whether the gap persists with IO maintenance, absent from this trial, is the open regimen question.
10 details 5 trials watching
Randomized phase II, 1:1, 3 institutions (MD Anderson, London Health Sciences Center, University of Colorado); unmasked. Closed early by DSMB after 49 of 74 enrolled pts were randomized (94 planned). Median follow-up 38.8 mo (28.3-61.4).
Stage IV NSCLC, ≤3 metastases (primary not counted), ECOG ≤2, no progression after front-line therapy: ≥4 cycles platinum doublet, or ≥3 mo EGFR TKI or crizotinib. Randomization dynamically balanced on met number, response, CNS mets, N stage and EGFR/ALK status.
LCT was RT, surgery or both to all active disease sites, modality chosen by MDT; concurrent chemoRT allowed for primary and regional nodes. Dose and fractionation not reported in source text (Appendix Table A1).
Primary: PFS from randomization. Secondary: OS, toxicity, time to new lesions. Powered (90%) for PFS 4 to 7 mo, HR 0.57; P<.10 deemed significant.
PFS, OS and survival-after-progression gains in the arm table above. Late LCT at progression correlated with OS in a multivariable model, HR 0.44 (0.18-1.06), P=.064; initial LCT HR 0.30 (0.12-0.75).
| Endpoint | LCT (n=25) | MT/O (n=24) | P |
|---|---|---|---|
| Median PFS (1° EP) | 14.2 mo (7.4-23.1) | 4.4 mo (2.2-8.3) | .022 |
| Median OS | 41.2 mo (18.9-NR) | 17.0 mo (10.1-39.8) | .017 |
| Survival after progression | 37.6 mo | 9.4 mo | .034 |
| Time to new lesions | 14.2 mo (5.7-24.3) | 6.0 mo (4.4-8.3) | 0.11 |
| Deaths | 11 of 25 | 18 of 24 | n/a |
No additional grade ≥3 toxicity beyond events reported in the initial publication.
The authors state no prior randomized trial had shown an OS benefit from LCT in lung cancer. They align their proposed oligometastatic definition (0-3 metastases, unconstrained by molecular profile) with most pts enrolled on SABR-COMET and the UT Southwestern randomized phase II trial, and point to NRG-LU002 as the phase III test.
Unmasked with heterogeneous physician-chosen maintenance. Post-progression and late-LCT analyses are exploratory, post-randomization, and exclude 3 MT/O pts who crossed over before progression. EGFR/ALK cohort n=8, too small to read.
The OS gain is carried by survival after progression, consistent with a window in which all sites are still treatable. Whether the effect survives IO maintenance and a full-size trial is unsettled.
CONSORT flow
Randomised phase II closed early for PFS benefit at 49 of 94 planned pts; OS is secondary and tested at P<.10. Needs phase III confirmation (e.g. NRG-LU002).
- Does the OS benefit hold with IO-era maintenance? active Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Phase 3n=339 · primary completion 2027-03 · phase III nivo/ipi ± LCT, stage IV NSCLCrecruiting First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. Phase 3n=124 · primary completion 2030-02 · phase III 1L IO-based SoC ± local ablative tx
- Does LCT add OS in EGFR/ALK-driven oligometastatic NSCLC? recruiting Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC Phase 2n=106 · primary completion 2026-11 · randomized TKI ± LCRT, EGFR/ALK/ROS oligometrecruiting Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer Phase 3n=154 · primary completion 2031-08 · phase III osimertinib ± primary resection, EGFR
- Does a phase III trial confirm the OS benefit? recruiting Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC Phase 3n=190 · primary completion 2026-04 · phase III maintenance ± LCRT, 1-5 mets
📚 Sources · 📄 1 paper
Abstract
The longer read
Before this update, the case for local consolidation in oligometastatic NSCLC rested on retrospective series, single-arm prospective work, and PFS signals from small randomized trials; the authors note that no randomized trial had yet shown an OS benefit from LCT in lung cancer. Converting a PFS result into an OS difference, mOS 41.2 vs 17.0 mo, is why this trial became a reference point alongside SABR-COMET and the UT Southwestern study. It also fixed the eligibility template much later work borrowed: three or fewer metastases, no progression after front-line systemic therapy.
The magnitude deserves skepticism proportional to how the trial ended. The DSMB closed accrual at 49 of a planned 94 after an interim look favored LCT, and trials stopped early for benefit tend to overstate effect size because stopping selects for a favorable random excursion. OS was secondary, tested at a P<.10 threshold, and the intervals are wide: the LCT arm's lower bound is 18.9 mo while the MT/O upper bound reaches 39.8 mo. Only 29 deaths inform the comparison. The multivariable OS HR 0.46 (0.21-0.99) holds after adjusting for metastasis count and EGFR/ALK status, but an upper bound that close to 1 reads as a direction more than a size.
The more informative signal is where the OS gap came from. Survival after progression was 37.6 vs 9.4 mo, while the share receiving late LCT did not differ by arm (P=.39). In the MT/O arm, seven progressors could not receive LCT because progression was polymetastatic. The reading the data most plainly support is a window argument: consolidation is feasible while disease is limited, and deferring it to progression lets a fraction of pts lose eligibility. The late-LCT association, HR 0.44 (0.18-1.06), fits that story, but it is a post-randomization comparison with selection built in, since pts fit and limited enough to get late LCT are prognostically favored.
For RT practice the gap is technique. LCT pooled surgery, RT and chemoRT to primary and nodes at MDT discretion, and dose and fractionation are not in the source text. The trial answers whether to treat all sites, not how much dose, or whether ablative stereotactic dosing outperforms conventional fractionation. The control arm was itself heterogeneous, physician-chosen maintenance or observation, unmasked.
What would make it wrong: the effect is an early-stopping artifact, or it does not persist on an immunotherapy backbone, which the trial (opened 2012) never included. Longer control-arm survival on IO maintenance would compress any absolute gain and could change where the consolidation window sits. The EGFR/ALK subset (n=8) cannot support a molecular claim either way. The authors frame their own subset analyses as provocative rather than paradigm-defining and call for phase III confirmation, NRG-LU002 among them. Until then the data support LCT within this trial's eligibility, not extrapolation to higher burden or IO-treated disease.